2 research outputs found
KliniÄka prosudba sedativnih svojstava acepromazin-ksilazina u kombinaciji s atropinom i njihov uÄinak na fizioloÅ”ke vrijednosti temperature, bila i disanja u pasa.
The purpose of this study was to clinically evaluate the sedative effects of different doses of acepromazinexylazine combinations with or without atropine in dogs. One hundred and twenty dogs of various breeds and both sexes were used in a prospective randomized, blinded clinical study. Dogs, presented to the Veterinary Clinic for various diagnostic and surgical procedures, were randomly divided into four groups (n=30/group) and received the following drug combinations intramuscularly: Group AX: acepromazine (0.05 mg kg-1) + Xylazine (0.5 mg kg-1), Group AXA: Acepromazine (0.05 mg kg 1) + Xylazine (0.5 mg kg-1) + Atropine (0.04 mg kg-1) Group LA HX: Acepromazine (Low dose: 0.03 mg kg-1) + Xylazine (High dose: 0.8 mg kg-1), Group HA-LX: Acepromazine (High dose: 0.08 mg kg-1) + Xylazine (Low dose: 0.3 mg kg-1). Heart and respiratory rates, electrocardiogram and rectal temperature were recorded before drug injection (baseline) and during maximum sedation. Sedation was scored using descriptive categories. Heart rate significantly decreased from the baseline following sedation in the AX, LA-HX and HA-LX groups. A significant reduction in respiratory rate was observed in all treatment groups. The median sedation score did not differ significantly between the groups; however, the quality of sedation was enhanced when atropine was added to the acepromazine-xylazine combination and a higher number of dogs were assigned score 3 in AXA group. No adverse effects were recorded during the study. The acepromazine-xylazine combination, particularly with atropine, can be used effectively for sedation and premedication before general anaesthesia in healthy dogs.Svrha ovog rada bila je kliniÄki procijeniti sedativne uÄinke razliÄitih doza acepromazin-ksilazina u kombinaciji s atropinom u pasa. Istraživanje je bilo provedeno na 120 nasumce odabranih pasa razliÄitih pasmina obaju spolova s dvostruko slijepim probama. Psi su bili kliniÄki obraÄivani na jednoj veterinarskoj klinici zbog potrebe za razliÄitim dijagnostiÄkim i kirurÅ”kim pregledima. Za potrebe istraživanja bili su podijeljeni u Äetiri skupine (30 pasa po skupini), a po skupinama su intramuskularno dobivali sljedeÄe kombinacije lijekova: skupina AX dobivala je acepromazin (0,05 mg kg-1) i ksilazin (0,5 mg kg-1), skupina AXA dobivala je acepromazin (0,05 mg kg-1), ksilazin (0,5 mg kg-1) i atropin (0,04 mg kg-1), skupina LA-HX dobivala je acepromazin (malu dozu od 0,03 mg kg-1) i ksilazin (veliku dozu od 0,8 mg kg-1), a skupina HA-LX acepromazin (veliku dozu od 0,08 mg kg-1) i ksilazin (malu dozu od 0,3 mg kg-1). Vrijednosti bila, frekvencije disanja, elektrokardiograma i rektalne temperature bile su izmjerene prije davanja sedativa te za vrijeme maksimalne sedacije. Sedacija je bila bodovana opisno. Vrijednosti bila znaÄajno su se smanjile nakon sedacije u pasa skupina AX, LA HX i HALX. ZnaÄajno smanjena frekvencija disanja bila je zabilježena u svim skupinama. Srednji broj bodova sedacije nije se znaÄajno razlikovao meÄu skupinama, ali je kvaliteta sedacije bila bolja kada je atropin bio dodan kombinaciji acepromazin-ksilazin te su tri boda bila dodijeljena veÄem broju pasa u skupini AXA. Nuspojave nisu bile zabilježene. Kombinacija acepromazin-ksilazin, osobito s atropinom, može se rabiti za uÄinkovitu sedaciju i premedikaciju prije opÄe anestezije u zdravih pasa
KliniÄka prosudba sedativnih svojstava acepromazin-ksilazina u kombinaciji s atropinom i njihov uÄinak na fizioloÅ”ke vrijednosti temperature, bila i disanja u pasa.
The purpose of this study was to clinically evaluate the sedative effects of different doses of acepromazinexylazine combinations with or without atropine in dogs. One hundred and twenty dogs of various breeds and both sexes were used in a prospective randomized, blinded clinical study. Dogs, presented to the Veterinary Clinic for various diagnostic and surgical procedures, were randomly divided into four groups (n=30/group) and received the following drug combinations intramuscularly: Group AX: acepromazine (0.05 mg kg-1) + Xylazine (0.5 mg kg-1), Group AXA: Acepromazine (0.05 mg kg 1) + Xylazine (0.5 mg kg-1) + Atropine (0.04 mg kg-1) Group LA HX: Acepromazine (Low dose: 0.03 mg kg-1) + Xylazine (High dose: 0.8 mg kg-1), Group HA-LX: Acepromazine (High dose: 0.08 mg kg-1) + Xylazine (Low dose: 0.3 mg kg-1). Heart and respiratory rates, electrocardiogram and rectal temperature were recorded before drug injection (baseline) and during maximum sedation. Sedation was scored using descriptive categories. Heart rate significantly decreased from the baseline following sedation in the AX, LA-HX and HA-LX groups. A significant reduction in respiratory rate was observed in all treatment groups. The median sedation score did not differ significantly between the groups; however, the quality of sedation was enhanced when atropine was added to the acepromazine-xylazine combination and a higher number of dogs were assigned score 3 in AXA group. No adverse effects were recorded during the study. The acepromazine-xylazine combination, particularly with atropine, can be used effectively for sedation and premedication before general anaesthesia in healthy dogs.Svrha ovog rada bila je kliniÄki procijeniti sedativne uÄinke razliÄitih doza acepromazin-ksilazina u kombinaciji s atropinom u pasa. Istraživanje je bilo provedeno na 120 nasumce odabranih pasa razliÄitih pasmina obaju spolova s dvostruko slijepim probama. Psi su bili kliniÄki obraÄivani na jednoj veterinarskoj klinici zbog potrebe za razliÄitim dijagnostiÄkim i kirurÅ”kim pregledima. Za potrebe istraživanja bili su podijeljeni u Äetiri skupine (30 pasa po skupini), a po skupinama su intramuskularno dobivali sljedeÄe kombinacije lijekova: skupina AX dobivala je acepromazin (0,05 mg kg-1) i ksilazin (0,5 mg kg-1), skupina AXA dobivala je acepromazin (0,05 mg kg-1), ksilazin (0,5 mg kg-1) i atropin (0,04 mg kg-1), skupina LA-HX dobivala je acepromazin (malu dozu od 0,03 mg kg-1) i ksilazin (veliku dozu od 0,8 mg kg-1), a skupina HA-LX acepromazin (veliku dozu od 0,08 mg kg-1) i ksilazin (malu dozu od 0,3 mg kg-1). Vrijednosti bila, frekvencije disanja, elektrokardiograma i rektalne temperature bile su izmjerene prije davanja sedativa te za vrijeme maksimalne sedacije. Sedacija je bila bodovana opisno. Vrijednosti bila znaÄajno su se smanjile nakon sedacije u pasa skupina AX, LA HX i HALX. ZnaÄajno smanjena frekvencija disanja bila je zabilježena u svim skupinama. Srednji broj bodova sedacije nije se znaÄajno razlikovao meÄu skupinama, ali je kvaliteta sedacije bila bolja kada je atropin bio dodan kombinaciji acepromazin-ksilazin te su tri boda bila dodijeljena veÄem broju pasa u skupini AXA. Nuspojave nisu bile zabilježene. Kombinacija acepromazin-ksilazin, osobito s atropinom, može se rabiti za uÄinkovitu sedaciju i premedikaciju prije opÄe anestezije u zdravih pasa